Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.
Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk
Family history of pancreatic ductal adenocarcinoma (PDAC)
Disqualifiers
BMI < 18.5 Kg/m2
Documented history of symptomatic hypoglycemia
Pregnant or breastfeeding women
Cognitively impaired individuals
Trial design
Design model
Single group
Treatments tested in this trial
intermittent fasting
Other interventionThey will fast for 16 consecutive hours each day and have an 8-hour window for eating.
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: Intermittent fastingExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Safety and adverse events (AEs).
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time frame
Through study completion; an average of 1 year.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: